Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38662055 | 1.00 | CSNK1A1 (0.53) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL27987378 | 0.92 | CSNK1A1 (0.50) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| Alcohol SCHEMBL28226404 | 0.91 | CSNK1A1 (0.49) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL8543220 | 0.85 | CSNK1A1 (0.49) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL10503929 | 0.82 | CSNK1A1 (0.49) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL8542514 | 0.82 | CSNK1A1 (0.49) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL9287236 | 0.80 | NISCH (0.64) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL3767684 | 0.80 | CSNK1A1 (0.41) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL14886257 | 0.78 | NISCH (0.61) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL24014343 | 0.78 | F2RL1 (0.46) | CSNK1A1TYRO3DYRK1BNISCHMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105859628-B | A kind of antimicrobial compound is to N imidazoles benzaldehyde contracting ortho-aminotoluene schiff bases and its preparation method and application | 清远职业技术学院 | 2018-08-07 | — | — | CN | claimed |
| CN-105457087-B | Titanium metal material of complex of iridium modification and its preparation method and application | 广西中医药大学 | 2018-06-29 | — | — | CN | claimed |
| CN-105288726-B | Titanium metal material of ruthenium complex modification and its preparation method and application | 广西中医药大学 | 2018-06-22 | — | — | CN | claimed |
| CN-105251055-B | The method that the antibacterial anti-cancer properties of titania nanotube are improved using complex of iridium | 广西中医药大学 | 2018-06-22 | — | — | CN | claimed |
| CN-105878236-A | Application of p-N-imidazole benzaldehyde o-toluidine Schiff base in resistance to staphylococcus aureus | 清远职业技术学院 | 2016-08-24 | — | — | CN | claimed |
| CN-105878235-A | Application of p-N-imidazole benzaldehyde o-toluidine Schiff base in resistance to salmonella | 清远职业技术学院 | 2016-08-24 | — | — | CN | claimed |
| CN-105859628-A | Antimicrobial compound p-N imidazole benzaldehyde condensed ortho-toluidine Schiff base and preparation method and application thereof | 清远职业技术学院 | 2016-08-17 | — | — | CN | claimed |
| CN-105457087-A | Titanium metal material modified by iridium complexes and preparation method and application thereof | UNIV GUANGXI CHINESE MEDICINE | 2016-04-06 | — | — | CN | claimed |
| CN-105288726-A | Ruthenium coordination compound modified titanium metal material, preparation method and uses thereof | UNIV GUANGXI CHINESE MEDICINE | 2016-02-03 | — | — | CN | claimed |
| CN-105251055-A | Method for improving antibacterial and anticancer performance of titanium dioxide nanotube by means of iridium complex | UNIV GUANGXI CHINESE MEDICINE | 2016-01-20 | — | — | CN | claimed |
| CN-100590120-C | Method of synthesizing p-N-imidazolyl benzaldehyde | QINGYUAN PROFESSION TECHNOLOGY COLLEGE | 2010-02-17 | — | — | CN | claimed |
| CN-101054365-A | Method of synthesizing p-N-imidazolyl benzaldehyde | QINGYUAN PROFESSION TECHNOLOGY (CN) | 2007-10-17 | — | — | CN | claimed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-105878235-B | To application of the N imidazoles benzaldehyde contracting ortho-aminotoluene schiff bases in terms of anti-salmonella | 清远职业技术学院 | 2019-01-15 | — | — | CN | disclosed |
| US-10131653-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-20 | — | — | US | disclosed |
| CN-105878236-B | To application of the N imidazoles benzaldehyde contracting ortho-aminotoluene schiff bases in terms of anti-Staphylococcus aureus | 清远职业技术学院 | 2018-10-26 | — | — | CN | disclosed |
| EP-1660011-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016272-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-0857171-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997015555-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131653-B2 | Heterocyclic compound | HCRTR1, HCRTR2, OXTR | CSNK1A1 2326/4885TYRO3 1528/4885DYRK1B 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.